SWOG Cancer Research Network clinical trials
Listed in the registry as: Research network.
The registry lists 339 studies whose lead sponsor is SWOG Cancer Research Network. 37 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the SWOG Cancer Research Network studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions SWOG Cancer Research Network leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 339. Browse all 339 →
- Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel CancersRecruitingNCT04205968Phase 2
- S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast CancerRecruitingNCT03723928Not applicable
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT05633615Phase 2
- Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT07393555Phase 2
- Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at DiagnosisRecruitingNCT07578116Phase 3
- Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and RadiationRecruitingNCT07615049Phase 3
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingNCT07636564Phase 2
- Adding Pirtobrutinib to the Usual Treatment for People With Newly Diagnosed Richter Transformation, The PIRAMID TrialRecruitingNCT07220187Phase 3
- Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingNCT07638722Phase 2
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06116682Phase 2
- Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06616584Phase 2/3
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)RecruitingNCT06031688Phase 2
- Testing an Educational Program to Improve Goals of Care Conversations Between Patients and Their Care TeamsRecruitingNCT07278739Not applicable
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerRecruitingNCT03678025Phase 3
- Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE TrialRecruitingNCT04510597Phase 3
- Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic LeukemiaEnrolling by invitationNCT06773936Phase 2
- Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck CancerEnrolling by invitationNCT07062354Phase 2
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingNCT07498205Phase 4
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingNCT04511013Phase 2
- Adding Capivasertib to Standard Treatment in HR Positive, HER2 Negative Metastatic Breast Cancer Based on ctDNA TestingNot yet recruitingNCT07802626Phase 3
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingNCT07383441Phase 3
- Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentRecruitingNCT05561387Phase 3
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)RecruitingNCT05642572Phase 2
- Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS MutationsRecruitingNCT06998940Phase 3
- Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerRecruitingNCT03851445Phase 2/3
- Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL AmyloidosisRecruitingNCT06022939Phase 3
- Comparing Cooling and/or Compression Approaches of Limbs for Prevention of Chemotherapy-Induced Peripheral NeuropathyRecruitingNCT05642611Phase 3
- Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid TumorsRecruitingNCT04871542
- Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic FistulaRecruitingNCT06807437Phase 3
- Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer SurvivorsRecruitingNCT07018869Phase 3
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingNCT06769126Phase 2
- Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene MutationRecruitingNCT05806515Phase 2
- Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the BodyRecruitingNCT06470243Phase 3
- Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine TumorsRecruitingNCT05040360Phase 2
- Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast CancerRecruitingNCT05929768Phase 3
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingNCT05890352Phase 2
- S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac ToxicityRecruitingNCT03418961Phase 3
- S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast CancerActive, not recruitingNCT01674140Phase 3
- S0820, Adenoma and Second Primary Prevention TrialActive, not recruitingNCT01349881Phase 3
- Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With CancerActive, not recruitingNCT03939481
- S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy DurationActive, not recruitingNCT04071457Phase 3
- Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)Active, not recruitingNCT04315324Phase 1/2
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast CancerActive, not recruitingNCT00070564Phase 3
- S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung CancerActive, not recruitingNCT04155034Phase 3
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersActive, not recruitingNCT02785952Phase 3
- S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung CancerCompletedNCT02438722Phase 2/3
- Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)Active, not recruitingNCT05096663Phase 2/3
- Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their SpousesActive, not recruitingNCT04960787Not applicable
- Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesActive, not recruitingNCT04647916Phase 2
- Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by SurgeryActive, not recruitingNCT03757949Phase 3